Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The influence of COVID-19 pandemic on intrauterine fetal demise and possible vertical transmission of SARS-CoV-2

Doğa Fatma Öcal a,*, Filiz Halıcı Öztürk a, Selvi Aydın Şenel a, Selcan Sinaci a, Fatma Didem Yücel Yetişkin a, Can Keven a, Bedia Dinç b, c, Ezgi Turgut a, Deniz Oluklu a, Özlem Moralıoğlu Tekin a, c, Dilek Şahin a, c

a Department of Obstetrics and Gynecology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey
b Department of Medical Microbiology, Turkish Ministry of Health, Ankara City Hospital, Ankara, Turkey
c University of Health Sciences, Istanbul, Turkey

ARTICLE INFO

Article history:
Accepted 2 March 2022

Keywords:
SARS-CoV-2
Vertical transmission
Second trimester
COVID-19
Placenta

ABSTRACT

Objective: The impact of COVID-19 on intrauterine fetal demise (IUFD) and vertical transmission of the SARS-CoV-2 from the mother to the fetus are crucial issues of the COVID-19 pandemic. In the current study, we aimed to detect the pandemic’s influence on the IUFD and evaluate the vertical transmission of the SARS-CoV-2 through analysis of placental tissues collected from PCR positive women with IUFD above 20 weeks of gestation.

Materials and methods: The pregnant women above 20 weeks of gestation and had a fetus intrauterine demised during pandemic were included in the study. The pregnant women screened for COVID-19. Vertical transmission searched from placental tissues of COVID-19 positive women by RT-PCR tests for the presence of SARS-CoV-2 RNA. The number of IUFD before the pandemic and during the pandemic compared to assess the influence of the COVID-19 pandemic on the IUFD ratio.

Results: Among 138 pregnant women with IUFD, 100 of them could screen for COVID-19 status. RT-PCR test results of 6 of the screened pregnant women were positive for SARS-CoV-2. Placental tissues of these six women were analyzed, and one test result was positive for SARS-CoV-2 RNA. The IUFD ratio was significantly increased during the pandemic.

Conclusion: It is clear that COVID-19 increases the IUFD ratio. Previous data for vertical transmission of SARS-CoV-2 during the second trimester is limited. We present the third case of literature that has positive placental results for SARS-CoV-2 RNA in the second trimester of pregnancy.

© 2022 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

A novel coronavirus, first detected in Wuhan, China, was named 2019-nCoV (for 2019 novel coronavirus) on January 7, 2020 [1,2]. On February 11, 2020, World Health Organization (WHO) officially called the disease Coronavirus Disease 19 (COVID-19). Etiologic virus of the COVID-19 disease was named Severe Acute Respiratory Syndrome (SARS)-CoV-2 by the International Committee on Taxonomy of Viruses [3]. On March 11, 2020, WHO declared the disease as a pandemic [4].

Pregnant women are classified as a vulnerable group, and in the light of previous experiences, more precautions were taken for them with COVID-19 [5,6]. It has been reported that poor obstetric outcomes, including preterm birth and fetal distress increase with COVID-19 [5,6].

The physiologic nature of pregnancy increases the risk of respiratory infections. The lung capacity and immunologic response decrease during pregnancy, making the mother prone to severe respiratory viral infections [7].

Since its initial identification, it is indicated that pregnancy may increase the severity of COVID-19. However, the knowledge on the influence of COVID-19 on pregnancy and obstetric outcomes is still limited.

In the present study, we aimed to evaluate the impact of COVID-19 on intrauterine fetal demise (IUFD) and search for the possible vertical transmission of SARS-CoV-2.
Material and methods

Participants

This prospective study was performed in Ankara City Hospital, Department of Perinatology, Ankara, Turkey, between August 1, 2020, and February 1, 2021. Our hospital is one of the leading national pandemic centers which handles above 10,000 deliveries yearly, and our department has extensive experience dealing with COVID-19 infected pregnant women [8].

Before initiating the study, the Ministry of Health of Turkey’s approval and ethical board approval from Ankara City Hospital Ethical Committee was obtained. The study protocol was performed according to the Declaration of Helsinki principles, and the written informed consent containing the details of the study was obtained from all the participants.

During the COVID-19 pandemic, pregnant women at or greater than 20 gestational weeks (gw) of pregnancy and had an intrauterine ex fetus were included in the study. The demographic characteristics including maternal age, gravidity, parity, number of the living children, number of miscarriages, co-morbid diseases, gestational age at diagnosis, pregnancy trimester at admission, symptoms of COVID-19, medications for COVID-19, the severity of illness, laboratory test results, mode of delivery were recorded. COVID-19 medications were edited according to the national guidelines at the time of admission [9].

COVID-19 infection screening tests were performed with RT-PCR kit. The pregnant women whose SARS-CoV-2 test results were positive, were screened for vertical transmission. After the delivery, samples were taken from the umbilical cord, amniotic membrane and placenta of the women with positive test results were evaluated for COVID-19 positivity.

Cases with IUFD before the pandemic and the total number of admissions during the study period were screened from the electronically recorded data of the hospital. Intrauterine fetal demise was defined as the intrauterine death of a fetus at any time during pregnancy [10].

Maternal and placental sampling

Nasopharyngeal and oropharyngeal swabs were used to screen the COVID-19 infection. To correctly perform the nasopharyngeal and oropharyngeal swab, pregnant women were seated with the back of their head against the headrest. An oropharyngeal sample was obtained by the swab. Subsequently, the same swab was inserted in the nose until reaching the nasopharynx’s posterior wall and rotated swab for a few seconds. After taking the samples, swabs were transported to the laboratory in a transport medium within 2 h and tested.

Placental samples were taken after delivery of the placenta immediately. Utmost care to keep sterility was taken to prevent contamination of the tissues. Approximately 5 cm tissue, including the umbilical cord, amnichorionic membrane and the placenta was taken. The sterile cover samples were transferred to the molecular virology laboratory in PBS [phosphate buffer saline] solution within 30 min.

Tissue analysis for COVID-19

In the molecular virology laboratory, approximately 2–3 mm³ of placental, amnichorionic membrane, and umbilical cord samples were taken and digested by 1000 microL of Buffer ATL [Qiagen, Hilden, Germany] and 50 microL of proteinase K [Qiagen Hilden, Germany] on a 65 °C heat block approximately for 3–4 h. After denaturation, for 10 min at 95 °C, vortex and spin processes were performed before dissolving 100 µL of the sample in 100 µL of Viral Nucleic Acid Extraction buffer [various manufacturers] and vortexing for 15 min before Polymerase Chain Reaction (PCR).

SARS-CoV2 tissues were detected by Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) method. Target genes were Orf1ab and N genes of SARS-CoV-2.

Real-time reverse-transcription PCR was performed by using Coronex COVID-19 RT-qPCR Detection Kit [DS Bio and Nano Technology, Ankara, Turkey] with 20 µL reaction containing five µL of RNA, 12.5 µL of CORONEX-Covid 19 DS Mix E [RT-qPCR Master mix], and 2.5 µL of CORONEX-Covid 19 DS PP1 [Orf1ab, N and RNP gene and primer-probe mix] in a thermal cycler device [Rotor-Gene Q, Qiagen, Germany] with a program; at 48 °C for 20 min for reverse transcription, followed by 95 °C for 2 min and then 35 cycles of 95 °C for 5 s, 60 °C for 10 s. Cycle threshold [Ct] values of less than 35 were defined as positive.

Statistical analyses

The statistical analyses were made by using IBM SPSS Statistics version 21.0 (IBM Corp. Armonk, NY). Descriptive data were expressed as mean ± standard deviation and minimum, median, maximum values after evaluating the normality of variables by using the Kolmogorov–Smirnov test. For comparison of the total numbers of admissions and IUFDs, Pearson-χ² test was used. An Independent sample t-test was used to compare the rates of IUFD before and during the pandemic. P < 0.05 values were defined as statistically significant.

Results

The perinatology clinic’s total hospital admission number before pandemic (August 2019–January 2020) was 15,722, and during pandemic (August 2020–January 2021) was 13,037. There was a significant decrease in hospital admission during the pandemic (p = 0.000). Table 1 shows the total hospital admission and IUFD numbers during the pandemic and before the pandemic. Despite the total number of hospital admissions significantly decreased, the total IUFD number increased during the pandemic. IUFD ratio [IUFD/Total admission number] was considerably higher during the pandemic period than during the period before the pandemic (1.1 vs. 0.79, p < 0.05).

There were 138 pregnant women with a fetus at or above 20 gw intrauterine demise. Thirty-eight of them could not be screened for COVID-19. Among the 100 women tested for COVID-19 with RT-PCR, six of them had positive results for SARS-CoV-2. Additionally, four women had positive SARS-CoV-2 results at the earlier gestational weeks of pregnancy.

The demographic properties and clinical characteristics of the women and the newborns are presented in Table 2. Sixteen (16%) women had at least one preexisting gestational or chronic condition, including diabetes, thrombophilia, leukemia, lymphoma, breast ca, epilepsy, hypertension, familial Mediterranean Fever (FMF), goiter, preeclampsia, myoma uteri. Sixteen women had additional obstetric pathology (16%). There was a balanced distribution among the fetuses for gender.

There were 63 women in the second trimester, while the number of women in the third trimester was 37.

Clinical features and laboratory results of the PCR-positive women are presented in Table 3. Among 6 SARS-CoV-2 positive tested women, 5 of them were in the second trimester. Four women had no symptoms. Half of the symptomatic women had symptoms as fever, cough, and fatigue, while the other half had myalgia and fatigue. Two women received medications for COVID-19.
None of the women had severe pneumonia, and there was no maternal mortality. SARS-CoV-2 test result of placental tissue was positive only in 1 woman. In the present case, the Rt-PCR results for SARS-CoV-2 in the umbilical cord and membrane were negative.

The case with positive placental SARS-CoV-2 test result was at 23 years old. The gravidity of the woman was 3 with two previous cesarean sections. The gestational age was 26 weeks. The woman was symptomatic for COVID-19, having fever, cough, and fatigue. Lopinavir-ritonavir, corticosteroid, IL-1 receptor antagonist were initiated for the patient. The fetus’s biometric measurements were compatible with the gestational age: 900 gr, ex-female fetus delivered by cesarean section.

Discussion

In the current study, we aimed to investigate the influence of COVID-19 on intrauterine fetal demise. The study results demonstrated a statistically significant increase in the rate of the IUFD during the pandemic according to the time before the COVID-19 pandemic. There was only one positive result of placental tissues among the pregnant women positive for SARS-CoV-2 who was in her second trimester of pregnancy.

The COVID-19 pandemic is not the first outbreak that humanity has ever faced. However, it is quite a challenging experience for the whole world. Based on the experience so far, we can say that older people are more vulnerable to COVID-19 with significant mortality risk. Pregnant patients, females, and children are less affected [11–13]. A systematic review reported that most of the COVID-19 positive pregnant women survived illness mildly [95.6% of 385 cases]. Previously, Sahin et al. presented the obstetric outcome of 533 COVID-19 positive pregnant women. Among 533 cases, COVID-19 was mild in 509 of them [95.5], while 2 pregnant women [0.4%] died [8].

Although COVID-19 progresses well in pregnant women, the mother and fetus’s risks are still not fully known. Two early meta-analyses reported high rates of poor obstetric outcomes of COVID-19 positive pregnant women [14,15]. A recent meta-analysis involving 1100 patients from 24 studies and searching the impact of COVID-19 on pregnancy outcomes, five maternal death cases, and three stillbirths out of 779 pregnancies reported. One of the three stillbirths was not related to COVID-19, while the influence of COVID-19 was unclear on the other two cases [16]. The same review emphasized that COVID-19 related fetal and neonatal mortality risk was shallow [17]. Abbas M et al. reported that COVID-19 may cause IUFD, anemia, respiratory failure, fetal infections, and thromboembolism in infected pregnant women [18].

In our previous study, the positivity rate of SARS-CoV-2 among the asymptomatic pregnant women admitted to the hospital for delivery was 1.4%. In the current study, the ratio of SARS-CoV-2 positivity among the pregnant women who have a dead fetus is 10%. The IUFD ratio increased during the pandemic. There may be several causes of this increase. During the pandemic, the vast majority of pregnant women avoided going to the hospitals because of...
the fear of contracting the infection. Therefore, the optimal antenatal care could not be provided.

Secondly, COVID-19 causes pathological changes in many systems in the human body. Previously published six cohort or case series studies assessed the placentas of COVID-19 positive mothers. Although the placentas were not directly evaluated for SARS-CoV-2, the vast majority of the placentas demonstrated common pathology like villous infarctions, fibrin deposition, chronic villitis, intramural fibrin deposition [19,20]. In another study evaluating the placentas for SARS-CoV-2 of 5 COVID-19 positive women, none of the placentas was positive for SARS-CoV-2. However, similar mal-perfusion findings were obtained from the pathologic assessment. Moreover, COVID-19 causes severe viral pneumonia among pregnant women. Maternal pneumonia is associated with adverse obstetric consequences as PPROM, IUFD, IUGR, PTL, miscarriage. COVID-19 induces microangiopathy and thrombus formation [19,20]. In another study evaluating the placenta, umbilical cord, and amniotic membranes with the RT-PCR method. The major limitation of this study is the placental tissues were not evaluated pathologically. Among six placental tissues, one of them was positive for the SARS-CoV-2 by evaluating the placenta, umbilical cord, and amniotic membra

In conclusion, we can exactly say that the COVID-19 pandemic has directly or indirectly increased IUFD rates. However, the vertical transmission of the virus still remains a mystery.

A more recent systematic review and meta-analysis that including 69 studies, claimed that vertical transmission of Sars-CoV-2 is possible during the third trimester of pregnancy [29].

Most of the previous studies include pregnant women in their third trimester; only 2 cases report women's obstetric outcomes in their second trimester [27–59]. The reports belong to earlier gestational weeks are few. In our previous study, we reported results of placenta or abortion material from the first trimester. All of the RT-PCR results for SARS-CoV-2 of abortion material were negative in that study [60].

The second trimester is the period in which the immune response reaches the lowest. Pregnant women should maintain the pregnancy despite a semi-allogenic fetus; therefore, the human organism responds to altering immune response [61].

This is the first study searching the influence of COVID-19 on intrauterine fetal demise above 20 weeks. Also, we report the third case with placental positivity for SARS-CoV-19 during the second trimester in the literature to the best of our knowledge.

Fetal demise is the fifth cause of death in the World, and 76% of cases are unexplained [62,63]. The infection rate among the reasons is varying from 5% to 22% [64].

Although we cannot establish a direct relationship between COVID-19 and IUFD, we cannot completely exclude the role of COVID-19 on IUFD. We screened the women for SARS-CoV-2 positivity at the admission to the hospital for IUFD. Therefore, we could not evaluate the previous status of the women for COVID-19. We were blind to the women who had asymptomatic COVID-19 during pregnancy, and we could not interpret the exact association between the COVID-19 and IUFD. Also, none of the placentas of the women with COVID-19 were pathologically evaluated. We did not know whether the placentas include any changes which may be attributed to COVID-19 or not. None of the pregnant women in our study had severe viral pneumonia, a pathologic condition associated with adverse obstetric outcomes.

In conclusion, we can exactly say that the COVID-19 pandemic has directly or indirectly increased IUFD rates. However, the vertical transmission of the virus still remains a mystery.

Future studies involving the pathologic examination of the placentas will shed light on this issue.

### Disclosure of conflict of interest

None.
References

[1] Schwartz DA, Graham AL. Potential maternal and infant outcomes from [SARS-CoV-2] COVID-19 infection of pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12(2):194.

[2] Ma K, Chen T, Han MF, Guo W, Ning Q. Management and clinical thinking of coronavirus disease 2019. Zhonghua Gai Kang Za Zhi 2020;28:6002.

[3] Gokula K, Bagda MA, Shafique Khan MA. Second-trimester pregnancy-related syndrome-coronavirus—the species and its viruses, a statement of the Coronavirus Study Group. bioRxiv 2020.02.07.937862.

[4] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91(1):57–60.

[5] Turan O, Hakan E, Dashraath P, Jeslyn WL, Wright A, Abdul-Kadir R. Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: a systematic review. Int J Gynecol Obstet 2020;205:226–36.

[6] Dubey P, Reddy S, Samuel M, Dwivedi AK. Maternal and neonatal characteristics and outcomes among COVID-19 infected women: an updated systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020;252:145–52.

[7] Rasmussen SA, Jamieson DJE, Uyeki TM. Effects of influenza on pregnancy and women infants. Am J Obstet Gynecol 2012;207:3–8.

[8] Sahin D, Tanacan A, Erol SA, Anuk AT, Yetiskin FDY, Keskin HL, et al. Updated experience of a tertiary pandemic center on 533 pregnant women with COVID-19 infection: a prospective cohort study from Turkey. Int J Gynecol Obstet 2020;151:328–34.

[9] Turkish Ministry of Health. General directorate of public Health, COVID-19 species and its viruses, a statement of the Coronavirus Study Group. bioRxiv 2020.02.07.937862.

[10] Abbas AM, Moris MS, Abdo MS, Monib FAE, Salah MA, Yousof EA, et al. Covid-19 coronavirus disease in China. Clin Infect Dis 2020;71:853–61.

[11] Toro FD, Gjoka M, Lorenzo GD, Santo DD, Seta FD, Maso G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol 2020;224:35–45.

[12] Baud D, Greub G, Favre G, Gengler C, Jaton K, Dubruc E, et al. Second-trimester pregnancy indicated no vertical transmission. J Med Virol 2020;92:1660–68.

[13] Zhang L, Zhou F, Zhou T, Zhang X, Li F, Gong M, et al. Newborns of women with COVID-19: a case series. J Obstet Gynaecol Res 2020;46:939–48.

[14] Khan S, Peng L, Siddique R, Majeed A, Almazroa MC, Paredes T, Carcero D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol 2020;37:361–5.

[15] Shen S, Huang B, Lao DJ, Li X, Yang F, Zhao Y, et al. Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi 2020;49:418–23.

[16] Kalafat E, Yaprak E, Cinar G, Osizk S, Uzun C, Varli B, Osizk S, Uzun C, et al. Lung ultrasound-trasound and computed tomographic findings in pregnant woman with COVID-19. Ultrasound Obstet Gynecol 2020:55:835–7.

[17] Khan S, Peng L, Siddique R, Nabi G, Nawsheron, Xue M, et al. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infect Control Hosp Epidemiol 2021;41:748–50.

[18] Li Y, Zhao R, Zheng C, Chen X, Wang J, Sheng X. Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2. China. Emerg Infect Dis 2020;26:1335–6.

[19] Rasmussen SA, Kelcey CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) during pregnancy: a case series. Preprints. Preprint posted online February 25, 2020.

[20] Lowe B, Bopp B. COVID-19 vaginal delivery - a case report. Aust N Z J Obstet Gynaecol 2020;60:465–6.

[21] Lu D, Sang L, Du S, Li T, Chang Y, XA. Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. J Matern Fetal Neonatal Med 2020;19:1e8.

[22] Zamaniyan M, Ebadi A, Aghajanpoor Mir S, Rahmani Z, Haghshenas M, Azizi S. Prenatal delivery in pregnancies complicated with critical COVID-19 pneumonia and vertical transmission. Pretn Diagn 2020;40:1759–61.

[23] Blauvelt CA, Chiu C, Donovan AL, Prath M, Shinmoto TA, George RB, et al. Acute respiratory distress syndrome in a preterm pregnant patient with coronavirus disease 2019 (COVID-19). Obstet Gynecol 2020;136:46–51.

[24] Buonosenso D, Raffaelli T, Tamburini E, Biasucci DG, Salvi S, Smargiassi A, et al. Clinical role of lung ultrasound for diagnosis and monitoring of COVID-19 pneumonia in pregnant women. Ultrasound Obstet Gynecol 2020;56:106–9.

[25] Gidlof S, Savchenko J, Brune T, Josefsen H. COVID-19 in pregnancy with comorbidities: more liberal testing strategy is needed. Acta Obstet Gynecol Scand 2020;99:1025.

[26] Hosier H, Backer D, Klesges LR, Saha S, Whang P, Shen L, et al. SARS-CoV-2 infection: a systematic review and meta-analysis. Am J Obstet Gynecol 2021;224(1):35.

[27] Fan C, Lei D, Fang C, Li C, Wang J, Liu C, et al. Perinatal transmission of SARS-CoV-2: should we worry? Clin Infect Dis 2020;27:362–4.

[28] Ziyad A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386:995–1007.

[29] Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA 2020;323:1846–8.

[30] Kusnadi MA, Djamaluddin Y, Poutseen SM, Malinowski AK, Vlachodimitropoulou E, Parks WT, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. CMAJ (Can Med Assoc J) 2020;192:6547–50.

[31] Patane L, Morotti D, Giunta MR, Sismondi C, Piccoli MG, Fregoli L, et al. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth. Am J Obstet Gynecol 2020;224(3):100145.

[32] Alzamora MC, Paredes T, Carcero D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol 2020;37:361–5.

[33] Chen S, Huang B, Lao DJ, Li X, Yang F, Zhao Y, et al. Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi 2020;49:418–23.

[34] Kompani M, Mandoukou Y, Poutseen SM, Malinowski AK, Vlachodimitropoulou E, Parks WT, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. CMAJ (Can Med Assoc J) 2020;192:6547–50.

[35] Patane L, Morotti D, Giunta MR, Sismondi C, Piccoli MG, Fregoli L, et al. Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth. Am J Obstet Gynecol 2020;224(3):100145.
[57] Algarroba GN, Rekawek P, Vahanian SA, Khullar P, Palaia T, Peltier MR, et al. Visualization of severe acute respiratory syndrome coronavirus 2 invading the human placenta using electron microscopy. Am J Obstet Gynecol 2020;223:e275–8.

[58] Vivanti AJ, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Cao JD, et al. Transplacental transmission of SARS-CoV-2 infection. Nat Commun 2020;11:3572.

[59] Yin MZ, Zhang L, Deng G, Han CF, Shen MX, Sun XY, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy in China: a retrospective cohort study. medRxiv. Preprint posted online April 11 2020. https://doi.org/10.1101/2020.04.07.20053744.

[60] Oztürk FH, Ocal DF, Tanacan A, Ayhan S, Ayhan Sc, Alimboga O, et al. Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. Placenta 2021;106:25–9.

[61] J E, J M, J W, V L, Smith R. Mechanisms of maternal immune tolerance during pregnancy. In: Recent advances in research on the human placenta. InTech; 2012.

[62] Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Lancet Ending Preventable Stillbirths Series study group. Lancet Stillbirth Epidemiology investigator group. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 2016;387(10018):587–603.

[63] Man J, Hutchinson JC, Heazell AE, Ashworth M, Levine S, Sebire NJ. Stillbirth and intrauterine fetal death: factors affecting determination of cause of death at autopsy. Ultrasound Obstet Gynecol 2016;48(5):566–73.

[64] Reinebrant HE, Leisher SH, Coory M, Henry S, Wojcieszek AM, Gardener G, et al. Making stillbirths visible: a systematic review of globally reported causes of stillbirth. BJOG 2018;125(2):212–24.